Top

Published in:

Open Access 01-12-2021 | Bronchial Asthma | Research article

Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses

Authors: Sangeetha Ramu, Hamid Akbarshahi, Sofia Mogren, Frida Berlin, Samuel Cerps, Mandy Menzel, Morten Hvidtfeldt, Celeste Porsbjerg, Lena Uller, Cecilia K. Andersson

Published in: BMC Immunology | Issue 1/2021

Abstract

Background

Mast cells (MCs) are known to contribute to both acute and chronic inflammation. Bronchial epithelial cells are the first line of defence against pathogens and a deficient anti-viral response has been suggested to play a role in the pathogenesis of asthma exacerbations. However, effects of MC mediators on bronchial epithelial immune response have been less studied. The aim of this study is to investigate the direct effects of stimulation with MC proteases, tryptase and chymase, on inflammatory and anti-viral responses in human bronchial epithelial cells (HBECs).

Method

Cultured BEAS-2b cells and primary HBECs from 3 asthmatic patients were stimulated with tryptase or chymase (0.1 to 0.5 μg/ml) for 1, 3, 6 and 24 h. To study the effects of MC mediators on the anti-viral response, cells were stimulated with 10 μg/ml of viral mimic Poly (I:C) for 3 and 24 h following pre-treatment with 0.5 μg/ml tryptase or chymase for 3 h. Samples were analysed for changes in pro-inflammatory and anti-viral mediators and receptors using RT-qPCR, western blot and Luminex.

Results

Tryptase and chymase induced release of the alarmin ATP and pro-inflammatory mediators IL-8, IL-6, IL-22 and MCP-1 from HBECs. Moreover, tryptase and chymase decreased the expression of E-cadherin and zonula occludens-1 expression from HBECs. Pre-treatment of HBECs with tryptase and chymase further increased Poly (I:C) induced IL-8 release at 3 h. Furthermore, tryptase significantly reduced type-I and III interferons (IFNs) and pattern recognition receptor (PRR) expression in HBECs. Tryptase impaired Poly (I:C) induced IFN and PRR expression which was restored by treatment of a serine protease inhibitor. Similar effects of tryptase on inflammation and anti-viral responses were also confirmed in primary HBECs from asthmatic patients.

Conclusion

MC localization within the epithelium and the release of their proteases may play a critical role in asthma pathology by provoking pro-inflammatory and alarmin responses and downregulating IFNs. Furthermore, MC proteases induce downregulation of epithelial junction proteins which may lead to barrier dysfunction. In summary, our data suggests that mast cells may contribute towards impaired anti-viral epithelial responses during asthma exacerbations mediated by the protease activity of tryptase.

Available only for authorised users

Bradding P. Human lung mast cell heterogeneity. Thorax. 2009;64(4):278–80. https://doi.org/10.1136/thx.2008.106427.CrossRefPubMed

Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefalt JS. Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol. 2011;127(4):905–12 e1–7.CrossRef

Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WW, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research program. Am J Respir Crit Care Med. 2011;183(3):299–309. https://doi.org/10.1164/rccm.201002-0295OC.CrossRefPubMed

Pesci A, Foresi A, Bertorelli G, Chetta A, Olivieri D. Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and normal subjects. Am Rev Respir Dis. 1993;147(3):684–9. https://doi.org/10.1164/ajrccm/147.3.684.CrossRefPubMed

Gibson PG, Allen CJ, Yang JP, Wong BJ, Dolovich J, Denburg J, et al. Intraepithelial mast cells in allergic and nonallergic asthma. Assessment using bronchial brushings. Am Rev Respir Dis. 1993;148(1):80–6. https://doi.org/10.1164/ajrccm/148.1.80.CrossRefPubMed

Tomioka M, Ida S, Shindoh Y, Ishihara T, Takishima T. Mast cells in bronchoalveolar lumen of patients with bronchial asthma. Am Rev Respir Dis. 1984;129(6):1000–5. https://doi.org/10.1164/arrd.1984.129.6.1000.CrossRefPubMed

Dougherty RH, Sidhu SS, Raman K, Solon M, Solberg OD, Caughey GH, et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol. 2010;125(5):1046–53 e8. https://doi.org/10.1016/j.jaci.2010.03.003.CrossRefPubMedPubMedCentral

Beasley R, Burgess C, Crane J, Pearce N, Roche W. Pathology of asthma and its clinical implications. J Allergy Clin Immunol. 1993;92(1 Pt 2):148–54. https://doi.org/10.1016/0091-6749(93)90097-Y.CrossRefPubMed

Laitinen A, Karjalainen EM, Altraja A, Laitinen LA. Histopathologic features of early and progressive asthma. J Allergy Clin Immunol. 2000;105(2 Pt 2):S509–13. https://doi.org/10.1016/S0091-6749(00)90052-6.CrossRefPubMed

10.

Moon TC, Befus AD, Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol. 2014;5:569.CrossRef

11.

Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev. 2007;217(1):141–54. https://doi.org/10.1111/j.1600-065X.2007.00509.x.CrossRefPubMedPubMedCentral

12.

Dvorak AM. Human mast cells. Adv Anat Embryol Cell Biol. 1989;114:1–107. https://doi.org/10.1007/978-3-642-74145-6_1.CrossRefPubMed

13.

Waern I, Jonasson S, Hjoberg J, Bucht A, Abrink M, Pejler G, et al. Mouse mast cell protease 4 is the major chymase in murine airways and has a protective role in allergic airway inflammation. J Immunol. 2009;183(10):6369–76. https://doi.org/10.4049/jimmunol.0900180.CrossRefPubMed

14.

Maryanoff BE, de Garavilla L, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med. 2010;181(3):247–53. https://doi.org/10.1164/rccm.200904-0627OC.CrossRefPubMed

15.

Krishna MT, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol. 2001;107(6):1039–45. https://doi.org/10.1067/mai.2001.115631.CrossRefPubMed

16.

Erin EM, Leaker BR, Zacharasiewicz AS, Higgins LA, Williams TJ, Boyce MJ, et al. Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. Allergy. 2005;60(12):1524–9. https://doi.org/10.1111/j.1398-9995.2005.00928.x.CrossRefPubMed

17.

Erin EM, Zacharasiewicz AS, Nicholson GC, Tan AJ, Higgins LA, Williams TJ, et al. Topical corticosteroid inhibits interleukin-4, −5 and −13 in nasal secretions following allergen challenge. Clin Exp Allergy. 2005;35(12):1608–14. https://doi.org/10.1111/j.1365-2222.2005.02381.x.CrossRefPubMed

18.

McNeil HP, Adachi R, Stevens RL. Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense. J Biol Chem. 2007;282(29):20785–9. https://doi.org/10.1074/jbc.R700017200.CrossRefPubMed

19.

Casale TB, Wood D, Richerson HB, Zehr B, Zavala D, Hunninghake GW. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest. 1987;80(5):1507–11. https://doi.org/10.1172/JCI113234.CrossRefPubMedPubMedCentral

20.

Montefort S, Gratziou C, Goulding D, Polosa R, Haskard DO, Howarth PH, et al. Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. J Clin Invest. 1994;93(4):1411–21. https://doi.org/10.1172/JCI117118.CrossRefPubMedPubMedCentral

21.

Mahmood MA, Rashid BM, Amin KAM, Tofiq DM, Nore BF. Correlation between serum Tryptase level and disease severity in asthmatic patients in the Sulaimani governorate. Int J Med Res Health. 2016;5(6):34–41.

22.

Salazar F, Ghaemmaghami AM. Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells. Front Immunol. 2013;4:356.CrossRef

23.

Tan WC. Viruses in asthma exacerbations. Curr Opin Pulm Med. 2005;11(1):21–6. https://doi.org/10.1097/01.mcp.0000146781.11092.0d.CrossRefPubMed

24.

Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47. https://doi.org/10.1084/jem.20041901.CrossRefPubMedPubMedCentral

25.

Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633–42. https://doi.org/10.1016/j.rmed.2009.06.014.CrossRefPubMed

26.

Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–61. https://doi.org/10.1183/09031936.01.00092101.CrossRefPubMed

27.

Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20(1):73–8. https://doi.org/10.1183/09031936.02.00278102.CrossRefPubMed

28.

Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103(11):1725–31. https://doi.org/10.1016/j.rmed.2009.05.002.CrossRefPubMed

29.

Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–85. https://doi.org/10.1016/j.jaci.2015.09.008.CrossRefPubMedPubMedCentral

30.

Williams JM, Duckworth CA, Burkitt MD, Watson AJ, Campbell BJ, Pritchard DM. Epithelial cell shedding and barrier function: a matter of life and death at the small intestinal villus tip. Vet Pathol. 2015;52(3):445–55. https://doi.org/10.1177/0300985814559404.CrossRefPubMedPubMedCentral

31.

Holtzman MJ, Byers DE, Alexander-Brett J, Wang X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat Rev Immunol. 2014;14(10):686–98. https://doi.org/10.1038/nri3739.CrossRefPubMedPubMedCentral

32.

Zhu J, Message SD, Qiu Y, Mallia P, Kebadze T, Contoli M, et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest. 2014;145(6):1219–29. https://doi.org/10.1378/chest.13-1567.CrossRefPubMedPubMedCentral

33.

Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax. 2014;69(3):240–6. https://doi.org/10.1136/thoraxjnl-2012-202909.CrossRefPubMed

34.

Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007;13(8):913–9. https://doi.org/10.1038/nm1617.CrossRefPubMed

35.

Ramu S, Menzel M, Bjermer L, Andersson C, Akbarshahi H, Uller L. Allergens produce serine proteases-dependent distinct release of metabolite DAMPs in human bronchial epithelial cells. Clin Exp Allergy. 2018;48(2):156–66. https://doi.org/10.1111/cea.13071.CrossRefPubMed

36.

Yuksel H, Turkeli A. Airway epithelial barrier dysfunction in the pathogenesis and prognosis of respiratory tract diseases in childhood and adulthood. Tissue Barriers. 2017;5(4):e1367458. https://doi.org/10.1080/21688370.2017.1367458.CrossRefPubMedPubMedCentral

37.

Steinke JW, Borish L. Immune responses in rhinovirus-induced asthma exacerbations. Curr Allergy Asthma Rep. 2016;16(11):78. https://doi.org/10.1007/s11882-016-0661-2.CrossRefPubMedPubMedCentral

38.

Akbarshahi H, Menzel M, Ramu S, Mahmutovic Persson I, Bjermer L, Uller L. House dust mite impairs antiviral response in asthma exacerbation models through its effects on TLR3. Allergy. 2018;73(5):1053–63. https://doi.org/10.1111/all.13378.CrossRefPubMed

39.

Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. Eur Respir J. 2016;48(5):1307–19. https://doi.org/10.1183/13993003.01129-2016.CrossRefPubMed

40.

Hinks TS, Zhou X, Staples KJ, Dimitrov BD, Manta A, Petrossian T, et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J Allergy Clin Immunol. 2015;136(2):323–33. https://doi.org/10.1016/j.jaci.2015.01.014.CrossRefPubMedPubMedCentral

41.

Stewart CE, Torr EE, Mohd Jamili NH, Bosquillon C, Sayers I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J Allergy (Cairo). 2012;2012:943982.

42.

Zhou X, Wei T, Cox CW, Jiang Y, Roche WR, Walls AF. Mast cell chymase impairs bronchial epithelium integrity by degrading cell junction molecules of epithelial cells. Allergy. 2019;74(7):1266–76. https://doi.org/10.1111/all.13666.CrossRefPubMed

43.

Van Cleemput J, Poelaert KCK, Laval K, Impens F, Van den Broeck W, Gevaert K, et al. Pollens destroy respiratory epithelial cell anchors and drive alphaherpesvirus infection. Sci Rep. 2019;9(1):4787. https://doi.org/10.1038/s41598-019-41305-y.CrossRefPubMedPubMedCentral

44.

Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005;116(3):531–6. https://doi.org/10.1016/j.jaci.2005.06.007.CrossRefPubMed

45.

Mullan CS, Riley M, Clarke D, Tatler A, Sutcliffe A, Knox AJ, et al. Beta-tryptase regulates IL-8 expression in airway smooth muscle cells by a PAR-2-independent mechanism. Am J Respir Cell Mol Biol. 2008;38(5):600–8. https://doi.org/10.1165/rcmb.2007-0082OC.CrossRefPubMed

46.

Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol. 1996;156(1):275–83.PubMed

47.

Zhu L, Lee B, Zhao F, Zhou X, Chin V, Ling SC, et al. Modulation of airway epithelial antiviral immunity by fungal exposure. Am J Respir Cell Mol Biol. 2014;50(6):1136–43. https://doi.org/10.1165/rcmb.2013-0357OC.CrossRefPubMedPubMedCentral

48.

Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204. https://doi.org/10.1038/nm1713.CrossRefPubMedPubMedCentral

49.

Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza a virus. J Biol Chem. 2005;280(7):5571–80. https://doi.org/10.1074/jbc.M410592200.CrossRefPubMed

50.

Ritter M, Mennerich D, Weith A, Seither P. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond). 2005;2:16.CrossRef

51.

Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis. 2003;24(7):1269–79. https://doi.org/10.1093/carcin/bgg078.CrossRefPubMed

52.

Menzel M, Ramu S, Calven J, Olejnicka B, Sverrild A, Porsbjerg C, et al. Oxidative stress attenuates TLR3 responsiveness and impairs anti-viral mechanisms in bronchial epithelial cells from COPD and asthma patients. Front Immunol. 2019;10:2765. https://doi.org/10.3389/fimmu.2019.02765.CrossRefPubMedPubMedCentral

53.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25(4):402–8.CrossRef

Title: Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses
Authors: Sangeetha Ramu
Hamid Akbarshahi
Sofia Mogren
Frida Berlin
Samuel Cerps
Mandy Menzel
Morten Hvidtfeldt
Celeste Porsbjerg
Lena Uller
Cecilia K. Andersson
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Bronchial Asthma
Interferon
Published in: BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI: https://doi.org/10.1186/s12865-021-00424-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

The inhibitory receptor Tim-3 fails to suppress IFN-γ production via the NFAT pathway in NK-cell, unlike that in CD4+ T cells

Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis

CD100 modulates cytotoxicity of CD8+ T cells in patients with acute myocardial infarction

Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study

Anti-inflammatory protein TNFα-stimulated gene-6 (TSG-6) reduces inflammatory response after brain injury in mice

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage